SBRA
Sabra Health Care REIT, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 25 ▼ 1 insider sell $302.5K at $19.86
- Jun 23 ▼ Citigroup downgrades
- Jul 7 Barclays initiates
- Jul 8 ▲ Truist Securities upgrades
- Jul 21 ▲ Sabra Health Care REIT raised full-year 2026 guidance, reflecting a…
- Aug 6 ▲ Raymond James upgrades
- Sep 8 ▼ 1 insider sell $4.2M at $20.83
- Nov 2 ▲ Sabra Health Care REIT reported Q3 2026 Normalized AFFO of $0.41 per…
- Nov 2 ▲ Earnings: SBRA Q3 2026 Earnings: EPS $0.41 (+140.5% vs est)
- Nov 11 ▼ 1 insider sell $209.8K at $20.98
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $4.7M.
- InstitutionsBULLISH
Q3 2026: 40 added (1 new), 20 trimmed or exited. Largest new: William Blair Investment Management $16.5M.
- AnalystsBULLISH
12 of 23 rate it Buy or better.
- Short sellersSTEADY
Short interest +0.9% to 17.88M shares. 8.3 days to cover, ≈6.8% of shares.
- TrendUPTREND
2% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| CENTERSQUARE INVESTMENT MANAGEMENT LLC | ADD | $145.3M |
| DEUTSCHE BANK AG\ | DOUBLED | $70.7M |
| JPMORGAN CHASE & CO | TRIM | $41.1M |
| Russell Investments Group, Ltd. | ADD | $36.6M |
| BARCLAYS PLC | DOUBLED | $26.6M |
| UBS Group AG | ADD | $23.7M |
| Invesco Ltd. | TRIM | $22.4M |
| HRT FINANCIAL LP | DOUBLED | $18.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
23 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 11, 2026 | UBS MAINTAIN | Neutral |
| Oct 19, 2026 | Wells Fargo MAINTAIN | Overweight |
| Oct 13, 2026 | UBS MAINTAIN | Neutral |
| Oct 13, 2026 | Barclays MAINTAIN | Equal-Weight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
FOSTER MICHAEL J Director Nov 11, 2026 | SELL | $209.8K |
MATROS RICHARD K Chair, CEO and President Sep 8, 2026 | SELL | $4.2M |
Kono Ann Director Aug 31, 2026 | AWARD | 791 sh |
KATZMANN LYNNE S Director Aug 31, 2026 | AWARD | 791 sh |
Costa Michael Lourenco Executive VP, CFO & Treasurer Aug 31, 2026 | AWARD | 4,158 sh |
Cusack Catherine Director Aug 31, 2026 | AWARD | 791 sh |
Barbarosh Craig A. Director Aug 31, 2026 | AWARD | 791 sh |
Malehorn Jeffrey A. Director Aug 31, 2026 | AWARD | 791 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
4 filings · 2 bullish · 0 bearish · 2 neutral- NEUTRAL 144Nov 10, 2026
Director Michael J. Foster filed a Form 144 notice of intent to sell 10,000 shares of Sabra Health…
The sale is small relative to market cap and Foster's holdings. Monitor for any subsequent Form 4 filings to confirm the sale executed; no immediate read-through for the stock.
- BULLISH 8-KNov 2, 2026
Sabra Health Care REIT reported Q3 2026 Normalized AFFO of $0.41 per share, above the Street…
The raised guidance and strong SHOP operating metrics (14.6% same-store NOI growth, 34.9% margin) signal accelerating earnings power from the portfolio shift toward higher-margin managed senior…
- BULLISH 8-KJul 21, 2026
Sabra Health Care REIT raised full-year 2026 guidance, reflecting a 7% increase in Normalized FFO…
The guidance raise and portfolio de-risking (Avamere re-tenanting, RCA mortgage resolution) are significant positive catalysts. Monitor H2 2026 for completion of the Avamere transition and further…
- NEUTRAL DEFA14AApr 24, 2026
Sabra Health Care REIT is holding its annual shareholder meeting to vote on the re-election of…
This is a standard annual meeting with no surprises. Monitor the voting results for any unexpected opposition to director elections or executive pay, which could signal shareholder discontent, but…
All SBRA filing & press-release reports (4)
- 144 reportNov 10, 2026
- 8-K reportNov 2, 2026
- 8-K reportJul 21, 2026
- DEFA14A reportApr 24, 2026